Literature DB >> 22790275

The modern treatment of haemophilia: a narrative review.

Massimo Franchini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22790275      PMCID： PMC3626468          DOI： 10.2450/2012.0166-11

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  29 in total

Review 1.  Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years.

Authors:  P M Mannucci
Journal:  Haemophilia       Date:  2000-07       Impact factor: 4.287

Review 2.  Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.

Authors:  Massimo Franchini; Annarita Tagliaferri; Carlo Mengoli; Mario Cruciani
Journal:  Crit Rev Oncol Hematol       Date:  2011-01-31       Impact factor: 6.312

3.  Treatment of haemophilia: building on strength in the third millennium.

Authors:  P M Mannucci
Journal:  Haemophilia       Date:  2011-11       Impact factor: 4.287

4.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 5.  Factor VIII safety: plasma-derived versus recombinant products.

Authors:  Alessandro Gringeri
Journal:  Blood Transfus       Date:  2011-04-12       Impact factor: 3.443

Review 6.  Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Authors:  A Iorio; S Halimeh; S Holzhauer; N Goldenberg; E Marchesini; M Marcucci; G Young; C Bidlingmaier; L R Brandao; C E Ettingshausen; A Gringeri; G Kenet; R Knöfler; W Kreuz; K Kurnik; D Manner; E Santagostino; P M Mannucci; U Nowak-Göttl
Journal:  J Thromb Haemost       Date:  2010-03-17       Impact factor: 5.824

7.  EUHASS: The European Haemophilia Safety Surveillance system.

Authors:  M Makris; G Calizzani; K Fischer; E A Gilman; C R M Hay; R Lassila; T Lambert; C A Ludlam; P M Mannucci
Journal:  Thromb Res       Date:  2011-01       Impact factor: 3.944

Review 8.  Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Thromb Haemost       Date:  2010-09-13       Impact factor: 5.249

9.  Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.

Authors:  L M Aledort; R J Navickis; M M Wilkes
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

Review 10.  Thrombotic complications of erythropoiesis-stimulating agents.

Authors:  Giuseppe Lippi; Massimo Franchini; Emmanuel J Favaloro
Journal:  Semin Thromb Hemost       Date:  2010-07-14       Impact factor: 4.180
View more
  25 in total

Review 1.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 3.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

4.  Learn more to do better... even for participants in haemophilia clinical trials.

Authors:  Antonio Coppola; Massimo Franchini
Journal:  Blood Transfus       Date:  2015-01-29       Impact factor: 3.443

Review 5.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

Review 6.  Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.

Authors:  Paolo A Cortesi; Lucia S D'Angiolella; Alessandra Lafranconi; Mariangela Micale; Giancarlo Cesana; Lorenzo G Mantovani
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

Review 7.  Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

Review 8.  Non-factor replacement therapy for haemophilia: a current update.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2018-02-14       Impact factor: 3.443

9.  The Italian institutional accreditation model for Haemophilia Centres.

Authors:  Gabriele Calizzani; Fabio Candura; Ivana Menichini; Romano Arcieri; Giancarlo Castaman; Alessandro Lamanna; Maria R Tamburrini; Antonio Fortino; Monica Lanzoni; Samantha Profili; Simonetta Pupella; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 10.  Recombinant activated factor VII in clinical practice: a 2014 update.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.